End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27,450 KRW | +0.73% | +4.57% | +6.60% |
Jun. 04 | First Solar, Qcells to be US government's preferred green-label panel vendors | RE |
Jun. 04 | First Solar, Qcells panels score green label preferred by US government | RE |
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Its low valuation, with P/E ratio at 8.85 and 3.55 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The stock, which is currently worth 2024 to 50.09 times its sales, is clearly overvalued in comparison with peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.60% | 1.97B | B | ||
+11.09% | 78.47B | B- | ||
+6.32% | 50B | B+ | ||
+6.72% | 50.03B | B | ||
+20.63% | 46.35B | B+ | ||
+13.76% | 42.36B | B+ | ||
+23.79% | 39.91B | B | ||
-1.32% | 28.8B | B | ||
-5.24% | 28.33B | B- | ||
-15.49% | 26.27B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A000880 Stock
- Ratings Hanwha Corporation